High Dose Tamoxifen in the Treatment of Recurrent High Grade Glioma: A Report of Clinical Stabilization and Tumour Regression

ABSTRACT: We present a case of recurrent glioma, previously treated with maximal surgery and radiation in which a high dose of tamoxifen has stabilized the tumour clinically and has resulted in it's radiologic regression. Given tamoxifen's relative lack of toxicity, it might serve as a useful adjuvant in the treatment of recurrent glioma.

[1]  M. Sporn,et al.  Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. , 1992, Cancer research.

[2]  I. Pollack,et al.  The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of "failed" patients. , 1992, Neurosurgery.

[3]  J. Uhm,et al.  Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro , 1991 .

[4]  A. Friedman,et al.  Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. , 1991, Journal of neurosurgery.

[5]  I. Pollack,et al.  Effect of tamoxifen on DNA synthesis and proliferation of human malignant glioma lines in vitro. , 1990, Cancer research.

[6]  M. Rowlands,et al.  Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. , 1990, Biochemical pharmacology.

[7]  S. Hipp,et al.  Intracarotid cisplatin chemotherapy for recurrent gliomas. , 1989, Journal of neurosurgery.

[8]  E. Oldfield,et al.  Intratumoral LAK cell and interleukin-2 therapy of human gliomas. , 1989, Journal of neurosurgery.

[9]  S. Legha,et al.  Tamoxifen in the treatment of breast cancer. , 1988, Annals of internal medicine.

[10]  P. Gutin,et al.  Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. , 1987, Journal of neurosurgery.

[11]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[12]  R. Mansel,et al.  Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. , 1986, Biochemical pharmacology.

[13]  F. V. von Eyben,et al.  Tamoxifen for brain metastases from breast cancer , 1986, Annals of neurology.

[14]  MD” Stig €3. Hansen,et al.  Monocular oscillopsia secondary to lens subluxation , 1986, Annals of neurology.

[15]  G. Mazzei,et al.  Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. , 1985, Biochemical pharmacology.

[16]  I. Weinstein,et al.  Inhibition of protein kinase C by tamoxifen. , 1985, Cancer research.

[17]  J. M. Davis,et al.  Tamoxifen-induced regression of cerebral metastases in breast carcinoma. , 1981, Cancer treatment reports.

[18]  L. Murphy,et al.  High-affinity anti-oestrogen binding site distinct from the oestrogen receptor , 1980, Nature.

[19]  J. Villemure,et al.  Protein kinase C inhibitors suppress cell growth in established and low-passage glioma cell lines. A comparison between staurosporine and tamoxifen. , 1993, Neurosurgery.

[20]  Weinstein Ib.  The role of protein kinase C in growth control and the concept of carcinogenesis as a progressive disorder in signal transduction. , 1990 .

[21]  I. Weinstein.  The role of protein kinase C in growth control and the concept of carcinogenesis as a progressive disorder in signal transduction. , 1990, Advances in second messenger and phosphoprotein research.